Pfizer Inc. [NYSE: PFE] loss -2.25% or -1.08 points to close at $46.82 with a heavy trading volume of 16428545 shares. The company report on August 26, 2022 that Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July.
If authorized, both Omicron BA.1-adapted and Omicron BA.4/BA.5-adapted bivalent vaccines will be available in the European Union as early as September.
It opened the trading session at $47.62, the shares rose to $47.96 and dropped to $46.701, the range by which the price of stock traded the whole day. The daily chart for PFE points out that the company has recorded -1.89% loss over the past six months. However, it is still -14.36% lower than its most recent low trading price.
If we look at the average trading volume of 19.68M shares, PFE reached to a volume of 16428545 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $58.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on May 23, 2022. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on April 06, 2022, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise from $59 to $70, while BofA Securities kept a Buy rating on PFE stock. On January 03, 2022, analysts increased their price target for PFE shares from 44 to 65.
The Average True Range (ATR) for Pfizer Inc. is set at 1.04, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 2.66. The Price to Book ratio for the last quarter was 3.00, with the Price to Cash per share for the same quarter was set at 5.80. Price to Free Cash Flow for PFE in the course of the last twelve months was 13.73 with Quick ratio for the last quarter at 1.20.
Trading performance analysis for PFE stock
Pfizer Inc. [PFE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.74. With this latest performance, PFE shares dropped by -7.69% in over the last four-week period, additionally sinking by -1.89% over the last 6 months – not to mention a drop of -1.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 34.06, with the RSI for the last a single of trading hit 29.94, and the three-weeks RSI is set at 37.47 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 50.34, while it was recorded at 47.81 for the last single week of trading, and 51.76 for the last 200 days.
Pfizer Inc. [PFE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +25.58 and a Gross Margin at +57.67. Pfizer Inc.’s Net Margin is presently recorded at +27.57.
Return on Equity for this stock inclined to 31.92, with Return on Assets sitting at 13.35.
Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.
Pfizer Inc. [PFE]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to -1.60%.
An analysis of insider ownership at Pfizer Inc. [PFE]
There are presently around $181,937 million, or 70.40% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 488,445,127, which is approximately 1.958% of the company’s market cap and around 0.04% of the total institutional ownership; BLACKROCK INC., holding 435,152,528 shares of the stock with an approximate value of $20.37 billion in PFE stocks shares; and STATE STREET CORP, currently with $13.45 billion in PFE stock with ownership of nearly 0.126% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,536 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 215,751,598 shares. Additionally, 1,410 investors decreased positions by around 115,963,186 shares, while 362 investors held positions by with 3,554,172,812 shares. The mentioned changes placed institutional holdings at 3,885,887,596 shares, according to the latest SEC report filing. PFE stock had 128 new institutional investments in for a total of 11,904,462 shares, while 122 institutional investors sold positions of 18,357,077 shares during the same period.